- Home
- WWR vs ANTX Comparison
WWR vs ANTX Comparison
Compare WWR & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WWR
- ANTX
- Stock Information
- Founded
- WWR 1977
- ANTX 2017
- Country
- WWR United States
- ANTX United States
- Employees
- WWR N/A
- ANTX N/A
- Industry
- WWR Metal Mining
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- WWR Basic Materials
- ANTX Health Care
- Exchange
- WWR Nasdaq
- ANTX Nasdaq
- Market Cap
- WWR 45.0M
- ANTX 41.8M
- IPO Year
- WWR N/A
- ANTX 2022
- Fundamental
- Price
- WWR $0.57
- ANTX $1.40
- Analyst Decision
- WWR Strong Buy
- ANTX Hold
- Analyst Count
- WWR 1
- ANTX 5
- Target Price
- WWR $2.50
- ANTX $3.50
- AVG Volume (30 Days)
- WWR 564.2K
- ANTX 96.0K
- Earning Date
- WWR 03-20-2025
- ANTX 03-25-2025
- Dividend Yield
- WWR N/A
- ANTX N/A
- EPS Growth
- WWR N/A
- ANTX N/A
- EPS
- WWR N/A
- ANTX N/A
- Revenue
- WWR N/A
- ANTX N/A
- Revenue This Year
- WWR N/A
- ANTX N/A
- Revenue Next Year
- WWR N/A
- ANTX N/A
- P/E Ratio
- WWR N/A
- ANTX N/A
- Revenue Growth
- WWR N/A
- ANTX N/A
- 52 Week Low
- WWR $0.40
- ANTX $0.87
- 52 Week High
- WWR $1.32
- ANTX $3.88
- Technical
- Relative Strength Index (RSI)
- WWR 37.61
- ANTX 54.19
- Support Level
- WWR $0.55
- ANTX $1.28
- Resistance Level
- WWR $0.64
- ANTX $1.55
- Average True Range (ATR)
- WWR 0.05
- ANTX 0.07
- MACD
- WWR 0.00
- ANTX -0.01
- Stochastic Oscillator
- WWR 28.62
- ANTX 40.74
About WWR Westwater Resources Inc.
Westwater Resources Inc focused on developing battery-grade natural graphite materials. The company is having one project which is the Westwater's coosa project which is currently used for the mining and extraction of graphite.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.